Prognostic predictive value of Ki-67 in stage I–II triple-negative breast cancer

References

• Harbeck N, Gnant M. Breast cancer. Lancet 389(10074), 1134–1150 (2017).
   PubMed Web of Science ®Google Scholar
• Gelmon K, Dent R, Mackey JR, Laing K, McLeod D, Verma S. Targeting triple-negative breast cancer: optimising therapeutic outcomes. Ann. Oncol. 23(9), 2223–2234 (2012).
   PubMed Web of Science ®Google Scholar
• Blows FM, Driver KE, Schmidt MK et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 7, e1000279 (2010).
   PubMed Web of Science ®Google Scholar
• Lehmann BD, Bauer JA, Chen X et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 121(7), 2750–2767 (2011).
   PubMed Web of Science ®Google Scholar
• Sun X, Kaufman PD. Ki-67: more than a proliferation marker. Chromosoma. 127(2), 175–186 (2018).
   PubMed Web of Science ®Google Scholar
• Arafah MA, Ouban A, Ameer OZ, Quek KJ. KI-67 LI expression in triple-negative breast cancer patients and its significance. Breast Cancer (Auckl). 15, 11782234211016977 (2021).
   Web of Science ®Google Scholar
• Wu Q, Ma G, Deng Y et al. Prognostic value of Ki-67 in patients with resected triple-negative breast cancer: a meta-analysis. Front Oncol. 9, 1068 (2019).
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Winer EP, Coates AS et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann. Oncol. 24(9), 2206–2223 (2013).
   PubMed Web of Science ®Google Scholar
• Penault-Llorca F, Radosevic-Robin N. Ki67 assessment in breast cancer: an update. Pathology 49(2), 166–171 (2017).
   PubMed Web of Science ®Google Scholar
• Focke CM, Bürger H, van Diest PJ et al. Interlaboratory variability of Ki67 staining in breast cancer. Eur. J. Cancer 84, 219–227 (2017).
   PubMed Web of Science ®Google Scholar
• Husni Cangara M, Miskad UA, Masadah R, Nelwan BJ, Wahid S. Gata-3 and KI-67 expression in correlation with molecular subtypes of breast cancer. Breast Dis. 40(Suppl. 1), S27–S31 (2021).
   PubMedGoogle Scholar
• Wang W, Wu J, Zhang P et al. Prognostic and predictive value of Ki-67 in triple-negative breast cancer. Oncotarget. 7(21), 31079–31087 (2016).
   PubMedGoogle Scholar
• Zhu X, Chen L, Huang B et al. The prognostic and predictive potential of Ki-67 in triple-negative breast cancer. Sci Rep. 10(1), 225 (2020).
   PubMed Web of Science ®Google Scholar
• Pan Y, Yuan Y, Liu G, Wei Y. P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients. PLoS ONE 12(2), e0172324 (2017).
   PubMed Web of Science ®Google Scholar
• Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 11(2), 174–183 (2010).
   PubMed Web of Science ®Google Scholar
• Aleskandarany MA, Green AR, Benhasouna AA et al. Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer. Breast Cancer Res. 14(1), R3 (2012).
   PubMed Web of Science ®Google Scholar
• Munzone E, Botteri E, Sciandivasci A et al. Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer. Breast Cancer Res. Treat. 134(1), 277–282 (2012).
   PubMed Web of Science ®Google Scholar
• Mrklić I, Ćapkun V, Pogorelić Z, Tomić S. Prognostic value of Ki-67 proliferating index in triple negative breast carcinomas. Pathol. Res. Pract. 209(5), 296–301 (2013).
   PubMed Web of Science ®Google Scholar
• Hammond ME, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Clin. Oncol. 28(16), 2784–2795 (2010).
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond MEH, Allison KH et al. Human epidermal growth factor receptor 2 testing in breast cancer: american society of clinical oncology/college of american pathologists clinical practice guideline focused update. J. Clin. Oncol. 36(20), 2105–2122 (2018).
   PubMed Web of Science ®Google Scholar
• Nielsen TO, Leung SCY, Rimm DL et al. Assessment of Ki67 in breast cancer: updated recommendations from the international ki67 in breast cancer working group. J. Natl Cancer Inst. 113(7), 808–819 (2021).
   PubMedGoogle Scholar
• Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 10(21), 7252–7259 (2004).
   PubMed Web of Science ®Google Scholar
• Mighri N, Mejri N, Boujemaa M et al. Association between epidemiological and clinico-pathological features of breast cancer with prognosis, family history, Ki-67 proliferation index and survival in Tunisian breast cancer patients. PLoS One. 17(9), e0269732 (2022).
   PubMed Web of Science ®Google Scholar
• Zenzola V, Cabezas-Quintario MA, Arguelles M et al. Prognostic value of Ki-67 according to age in patients with triple-negative breast cancer. Clin Transl Oncol. 20(11), 1448–1454 (2018).
   PubMed Web of Science ®Google Scholar
• Setiawan K, Suryawisesa IB, Widiana IK, Sudarsa IW. Does a 40% cutoff point for Ki-67 expression have a role in identifying the development of distant metastasis within 2 years in locally advanced triple negative breast cancer patients? Eur J Breast Health. 19(4), 274–278 (2023).
   PubMed Web of Science ®Google Scholar
• Goetz MP, Kalari KR, Suman VJ et al. Tumor sequencing and patient-derived xenografts in the neoadjuvant treatment of breast cancer. J. Natl Cancer Inst. 109(7), djw306 (2017).
   PubMedGoogle Scholar
• Wang RX, Chen S, Jin X, Shao ZM. Value of Ki-67 expression in triple-negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin. Sci Rep. 6, 30091 (2016).
   PubMed Web of Science ®Google Scholar
• Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 378(9805), 1812–1823 (2011).
   PubMed Web of Science ®Google Scholar
• Burstein MD, Tsimelzon A, Poage GM et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 21(7), 1688–1698 (2015).
   PubMed Web of Science ®Google Scholar
• Jiang YZ, Ma D, Suo C et al. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies. Cancer Cell. 35(3), 428–440.e5 (2019).
   PubMed Web of Science ®Google Scholar
• Zagorac I, Lončar B, Dmitrović B, Kralik K, Kovačević A. Correlation of folate receptor alpha expression with clinicopathological parameters and outcome in triple negative breast cancer. Ann Diagn Pathol. 48, 151596 (2020).
   PubMed Web of Science ®Google Scholar
• Shetty J, Rao C. Expression of E cadherin and Ki 67: emerging prognostic markers in triple-negative breast cancer. Indian J Surg Oncol. 10(2), 377–381 (2019).
   PubMed Web of Science ®Google Scholar
• Vihervuori H, Korpinen K, Autere TA, Repo H, Talvinen K, Kronqvist P. Varying outcomes of triple-negative breast cancer in different age groups-prognostic value of clinical features and proliferation. Breast Cancer Res. Treat. 196(3), 471–482 (2022).
   PubMed Web of Science ®Google Scholar
• Nishimura R, Osako T, Okumura Y et al. Triple negative breast cancer: an analysis of the subtypes and the effects of menopausal status on invasive breast cancer. J Clin Med. 11(9), 2331 (2022).
   PubMed Web of Science ®Google Scholar
• Urru SAM, Gallus S, Bosetti C et al. Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients. BMC Cancer. 18(1), 56 (2018).
   PubMedGoogle Scholar
• Gluz O, Nitz U, Liedtke C et al. Comparison of neoadjuvant nab-paclitaxel + carboplatin vs nab-paclitaxel + gemcitabine in triple-negative breast cancer: randomized WSG-ADAPT-TN trial results. J. Natl Cancer Inst. 110(6), 628–637 (2018).
   PubMedGoogle Scholar
• Zhang H, Wang Z, Liu W, Wang P, Zhang X. Breast-conserving surgery in triple-negative breast cancer: a retrospective cohort study. Evid Based Complement Alternat Med. 5431563 (2023).
   PubMed Web of Science ®Google Scholar
• van den Ende NS, Nguyen AH, Jager A, Kok M, Debets R, van Deurzen CHM. Triple-negative breast cancer and predictive markers of response to neoadjuvant chemotherapy: a systematic review. Int J Mol Sci. 24(3), 2969 (2023).
   PubMed Web of Science ®Google Scholar
• Toss A, Venturelli M, Civallero M et al. Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy. Front Oncol. 12, 1016295 (2022).
   PubMedGoogle Scholar
• Gamucci T, Pizzuti L, Sperduti I et al. Neoadjuvant chemotherapy in triple-negative breast cancer: a multicentric retrospective observational study in real-life setting. J. Cell. Physiol. 233(3), 2313–2323 (2018).
   PubMed Web of Science ®Google Scholar
• Zhu M, Yu Y, Shao X, Zhu L, Wang L. Predictors of response and survival outcomes of triple negative breast cancer receiving neoadjuvant chemotherapy. Chemotherapy 65(3–4), 101–109 (2020).
   PubMed Web of Science ®Google Scholar
• Riaz N, Idress R, Habib S, Lalani EN. Lack of androgen receptor expression selects for basal-like phenotype and is a predictor of poor clinical outcome in non-metastatic triple negative breast cancer. Front Oncol. 10, 1083 (2020).
   PubMed Web of Science ®Google Scholar
• Mohammed AA, Elsayed FM, Algazar M, Rashed HE, Anter AH. Neoadjuvant chemotherapy in triple negative breast cancer: correlation between androgen receptor expression and pathological response. Asian Pac J Cancer Prev. 21(2), 563–568 (2020).
   PubMedGoogle Scholar
• Naimi A, Soltan M, Amjadi E, Goli P, Kefayat A. Androgen receptor expression and its correlation with clinicopathological parameters in iranian patients with triple negative breast cancer. Iran J Pathol. 15(3), 239–244 (2020).
   PubMedGoogle Scholar
• Astvatsaturyan K, Yue Y, Walts AE, Bose S. Androgen receptor positive triple negative breast cancer: clinicopathologic, prognostic, and predictive features. PLoS One. 13(6), e0197827 (2018).
   PubMed Web of Science ®Google Scholar
• Zhang G, Shi Z, Liu L et al. The prognostic relevance of p53 and Ki-67 to chemotherapy sensitivity and prognosis in triple-negative breast cancer. Transl Cancer Res. 10(2), 1082–1087 (2021).
   PubMed Web of Science ®Google Scholar
• Luo Y, Huang W, Zhang H, Liu G. Prognostic significance of CD117 expression and TP53 missense mutations in triple-negative breast cancer. Oncol Lett. 15(5), 6161–6170 (2018).
   PubMed Web of Science ®Google Scholar
• Park MH, Kwon SY, Choi JE, Gong G, Bae YK. Intratumoral CD103-positive tumour-infiltrating lymphocytes are associated with favourable prognosis in patients with triple-negative breast cancer. Histopathology 77(4), 560–569 (2020).
   PubMed Web of Science ®Google Scholar
• Motamedi B, Rafiee-Pour HA, Khosravi MR et al. Prolactin receptor expression as a novel prognostic biomarker for triple negative breast cancer patients. Ann Diagn Pathol. 46, 151507 (2020).
   PubMed Web of Science ®Google Scholar
• Yoshikawa K, Ishida M, Yanai H, Tsuta K, Sekimoto M, Sugie T. Adipophilin expression is an independent marker for poor prognosis of patients with triple-negative breast cancer: an immunohistochemical study. PLoS One. 15(11), e0242563 (2020).
   PubMed Web of Science ®Google Scholar
• Badowska-Kozakiewicz AM, Budzik MP, Liszcz A et al. Clinicopathological factors associated with novel prognostic markers for patients with triple negative breast cancer. Arch Med Sci. 15(6), 1433–1442 (2019).
   PubMed Web of Science ®Google Scholar
• Ozretic P, Alvir I, Sarcevic B et al. Apoptosis regulator Bcl-2 is an independent prognostic marker for worse overall survival in triple-negative breast cancer patients. Int J Biol Markers. 33(1), 109–115 (2018).
   PubMed Web of Science ®Google Scholar
• Loi S, Michiels S, Salgado R et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann. Oncol. 25(8), 1544–1550 (2014).
   PubMed Web of Science ®Google Scholar
• Adams S, Gray RJ, Demaria S et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J. Clin. Oncol. 32(27), 2959–2966 (2014).
   PubMed Web of Science ®Google Scholar
• Pruneri G, Vingiani A, Bagnardi V et al. Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer. Ann. Oncol. 27(2), 249–256 (2016).
   PubMed Web of Science ®Google Scholar
• Yu H, Meng X, Chen H et al. Correlation between mammographic radiomics features and the level of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer. Front Oncol. 10, 412 (2020).
   PubMed Web of Science ®Google Scholar
• Zhang L, Wang XI, Zhang S. Tumor-infiltrating lymphocyte volume is a better predictor of neoadjuvant therapy response and overall survival in triple-negative invasive breast cancer. Hum. Pathol. 80, 47–54 (2018).
   PubMed Web of Science ®Google Scholar
• Abuhadra N, Sun R, Yam C et al. Predictive roles of baseline stromal tumor-infiltrating lymphocytes and ki-67 in pathologic complete response in an early-stage triple-negative breast cancer prospective trial. Cancers (Basel). 15(13), 3275 (2023).
   PubMed Web of Science ®Google Scholar
• Nottegar A, Veronese N, Senthil M et al. Extra-nodal extension of sentinel lymph node metastasis is a marker of poor prognosis in breast cancer patients: a systematic review and an exploratory meta-analysis. Eur. J. Surg. Oncol. 42(7), 919–925 (2016).
   PubMed Web of Science ®Google Scholar
• Aziz S, Wik E, Knutsvik G et al. Extra-nodal extension is a significant prognostic factor in lymph node positive breast cancer. PLoS ONE 12(2), e0171853 (2017).
   PubMed Web of Science ®Google Scholar
• Gujam FJ, Going JJ, Edwards J, Mohammed ZM, McMillan DC. The role of lymphatic and blood vessel invasion in predicting survival and methods of detection in patients with primary operable breast cancer. Crit. Rev. Oncol. Hematol. 89(2), 231–241 (2014).
   PubMed Web of Science ®Google Scholar
• Zhang S, Zhang D, Yi S et al. The relationship of lymphatic vessel density, lymphovascular invasion, and lymph node metastasis in breast cancer: a systematic review and meta-analysis. Oncotarget. 8(2), 2863–2873 (2017).
   PubMedGoogle Scholar
• Chen L, Zhang J, Chen J et al. Post-operative radiotherapy is beneficial for T1/T2 triple negative breast cancer patients with four or more positive lymph nodes. Oncotarget. 8(26), 42917–42925 (2017).
   PubMedGoogle Scholar
• Abdulkarim BS, Cuartero J, Hanson J, Deschênes J, Lesniak D, Sabri S. Increased risk of locoregional recurrence for women with T1–2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. J. Clin. Oncol. 29(21), 2852–2858 (2011).
   PubMed Web of Science ®Google Scholar
• He MY, Rancoule C, Rehailia-Blanchard A et al. Radiotherapy in triple-negative breast cancer: current situation and upcoming strategies. Crit. Rev. Oncol. Hematol. 131, 96–101 (2018).
   PubMed Web of Science ®Google Scholar